22 Cherry Hill Drive
455 articles with Abiomed
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET.
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference.
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
Abiomed, a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock patients during the Society for Cardiovascular Angiography and Interventions 2022 Scientific Sessions, May 19 – 22, in Atlanta.
ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022.
Abiomed announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery as part of the heart pump’s U.S. Food and Drug Administration Early Feasibility Study.
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.
The versatility and innovation of Abiomed’s Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world.
Abiomed, Inc. announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40am.
ABIOMED, Inc. today announced financial results for the quarter ended December 31, 2021.
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022.
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
Regulators in three countries have granted approvals to Impella surgical products, as Abiomed continues to execute its strategy for sustainable growth with new products, new indications and new geographies.
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference.
Abiomed, Inc. announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2021 on Wednesday, December 1, 2021, at 3:00pm ET and at the Piper Sandler Virtual Healthcare Conference on December 2, 2021, at 11:00am ET.
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps .
The 2021 guidelines of the European Society of Cardiology raise the recommendation level for short-term mechanical circulatory support systems such as Impella heart pumps from Class IIb ("may be considered") to Class IIa ("should be considered").
TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
Abiomed's (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021 , the annual scientific symposium of the Cardiovascular Research Foundation.
Abiomed, Inc. today announced financial results for the quarter ended September 30, 2021.
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022.
The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed ’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump.
Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced financial results for the quarter ended June 30, 2021.